Drugs / RPT193
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06087978 | Jul → Oct 2023 | — | RAPT Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04271514 | Aug 2019 → Apr 2021 | atopic eczema | RAPT Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05935332 | Jul 2023 → Jun 2024 | asthma | RAPT Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05399368 | Jun 2022 → May 2024 | atopic eczema | RAPT Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPT193 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087978 ↗ |
| Action | Inhibit | “Antagonist of the CCR4 chemokine receptor” NCT04271514 ↗ |
| Route | Oral | “RPT193 400 mg oral tablet administered daily for 16 weeks” NCT05399368 ↗ |
| Target | CCR4 | “antagonist of the C-C motif chemokine receptor 4 (CCR4)” NCT05399368 ↗ |